Form 4: Praxis Precision Medicines Director, Jill DeSimone, Acquires Stock Options
SEC Filing Form 4
Director Jill DeSimone acquired stock options in Praxis Precision Medicines, Inc. on June 5, 2024.
Summary
- Jill DeSimone, a director of Praxis Precision Medicines, Inc., filed a Form 4 on June 6, 2024, reporting a transaction.
- On June 5, 2024, DeSimone acquired stock options to purchase 8,566 shares of common stock at an exercise price of $44.25.
- The options vest in twelve equal monthly installments over one year, commencing on June 5, 2024.
- Following the transaction, DeSimone directly owns options for 8,566 shares.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It simply reports a transaction by a company director.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows the public to see how company leadership is investing in the company.
Stakeholder Impact
- The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock option grant and commencement of vesting. |
| 06/05/2034 | Expiration date of the stock options. |
| 06/06/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.